Xenon Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2012
Cash & Equivalents	148.64	57.24	175.69	45.01	24.76	67.75	20.49	17.1	58.65	72.03	Upgrade
Short-Term Investments	489.44	534.85	376.09	131.99	116.6	51.55	23.18	47.05	0	12.02	Upgrade
Cash & Cash Equivalents	638.08	592.09	551.77	177	141.36	119.31	43.67	64.15	58.65	84.04	Upgrade
Cash Growth	7.77%	7.31%	211.74%	25.21%	18.48%	173.22%	-31.93%	9.37%	-30.21%	70.55%	Upgrade
Receivables	0.87	0.99	2.77	1.82	0.81	0.15	0.44	0.2	0.32	0.22	Upgrade
Other Current Assets	6.01	7.23	4.48	2.96	2.7	1.88	0.72	1.33	1.9	0.69	Upgrade
Total Current Assets	644.96	600.3	559.02	181.78	144.87	121.33	44.82	65.68	60.87	84.94	Upgrade
Property, Plant & Equipment	18.85	16.91	12.52	6.88	2.59	0.99	1.07	1.4	1.99	2.48	Upgrade
Long-Term Investments	292.79	128.68	0	0	0	0	0	0	0	0	Upgrade
Other Long-Term Assets	8.2	8.26	0.47	0.52	0.24	0.11	0.23	0.41	1.09	0	Upgrade
Total Long-Term Assets	319.84	153.85	12.99	7.4	2.83	1.1	1.3	1.81	3.08	2.48	Upgrade
Total Assets	964.8	754.15	572.01	189.19	147.7	122.43	46.12	67.49	63.95	87.42	Upgrade
Accounts Payable	25.97	22.21	13.72	10.87	8.82	4.12	3.38	3.59	2.63	2.66	Upgrade
Deferred Revenue	0	0	0	3.64	30.45	0	0	0	0.16	11.78	Upgrade
Current Debt	1.3	0.49	0.61	0.27	4.82	0	0.7	0	0	0	Upgrade
Other Current Liabilities	0	0	0	0	-0.71	0	0	0	0	-0.16	Upgrade
Total Current Liabilities	27.27	22.7	14.32	14.78	43.38	4.12	4.08	3.59	2.78	14.29	Upgrade
Long-Term Debt	9.6	9.95	7.65	3.05	11.63	15.01	6.1	0	0	0	Upgrade
Other Long-Term Liabilities	0	0	0	0	0.71	0	0	0	0.13	0.35	Upgrade
Total Long-Term Liabilities	9.6	9.95	7.65	3.05	12.34	15.01	6.1	0	0.13	0.35	Upgrade
Total Liabilities	36.88	32.65	21.97	17.83	55.72	19.13	10.19	3.59	2.92	14.64	Upgrade
Total Debt	10.9	10.44	8.26	3.32	16.45	15.01	6.8	0	0	0	Upgrade
Debt Growth	4.48%	26.38%	149.08%	-79.85%	9.56%	120.66%	-	-	-	-	Upgrade
Retained Earnings	-665.14	-482.75	-357.37	-278.49	-249.66	-207.89	-173.39	-142.68	-119.69	-103.73	Upgrade
Comprehensive Income	-0.08	-3	-0.99	-0.99	-0.99	-0.99	-0.99	-0.99	-0.99	-0.99	Upgrade
Shareholders' Equity	927.92	721.5	550.03	171.36	91.98	103.3	35.93	63.9	61.03	72.78	Upgrade
Net Cash / Debt	627.18	581.65	543.52	173.68	124.91	104.29	36.86	64.15	58.65	84.04	Upgrade
Net Cash / Debt Growth	7.83%	7.02%	212.94%	39.05%	19.77%	182.92%	-42.53%	9.37%	-30.21%	70.55%	Upgrade
Net Cash Per Share	9.38	9.61	12.46	5.03	4.82	5.37	2.05	4.14	4.11	21.20	Upgrade
Working Capital	617.69	577.6	544.7	167	101.49	117.21	40.74	62.09	58.08	70.66	Upgrade
Book Value Per Share	13.87	11.92	12.61	4.96	3.55	5.32	2.00	4.12	4.27	22.99	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).